A Study Investigating the Clinical Parameters Associated With the Use of Ryzodeg® (Insulin Degludec/Insulin Aspart) in a Real-world Adult Population With Type 2 Diabetes in South Korea

Inclusion Criteria: * Male or female, age above or equal to 19 years at the time of Ryzodeg® initiation * Type 2 diabetes mellitus patients * Treated with any basal-insulin (plus/minus OAD (Oral Antidiabetic Drug)) or premix-insulin (plus/minus OAD) for at least 26 weeks prior to switching to Ryzodeg® * Treated with Ryzodeg® (plus/minus OAD) for at least 26 weeks after switch from any basal insulin (plus/minus OAD) or premix insulin (plus/minus OAD) * At least more than once documented medical visit for 26weeks (plus/minus 6 weeks) after Ryzodeg® initiation * Minimum available data : age, type of diabetes at the time of Ryzodeg® initiation, HbA1c \[Three values: most recent value within 26 weeks (plus/minus 6 weeks) prior to Ryzodeg® initiation, a value of Ryzodeg® initiation date (plus/minus 6 week), and a value in the first 26 weeks (plus/minus 6 weeks) after Ryzodeg® initiation\] * The decision to treat with Ryzodeg® was taken by treating physician independently from decision to include patient in study. Exclusion Criteria: * Patients treated with any diabetic investigational drug within 26 weeks before or after the initiation of Ryzodeg® * Patients switching to Ryzodeg® below 26 weeks prior to the data collection date * Patients not treated with any basal-insulin or premix-insulin at least 26 weeks prior to receiving Ryzodeg® * Patients treated by continuous subcutaneous insulin infusion prior to receiving Ryzodeg® * Pregnancy patient * Patients not treated with the local licensed Ryzodeg®